Protokoll Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: https://doublebp.com/news/blog/ Follow us on LinkedIn, Facebook and Twitter! Information on Double Bond [...]
Årsredovisning Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: https://doublebp.com/news/blog/ Follow us on LinkedIn, Facebook and Twitter! Information on Double Bond [...]
Kallelse Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Fullmakt Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Bokslutskommuniké 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Website: http://www.doublebp.com/ E-mail: info@doublebp.com Follow us on LinkedIn, Facebook and Twitter! Information on Double [...]
EANS 2026. Listen to an overview here: audio file (SV) audio file (EN) Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor [...]
Double Bond Pharmaceutical will conduct an upcoming post-marketing study of Temodex to examine real-world survival outcomes in clinical practice. The results will help validate the SI-053 program. Listen to an overview here: audio file (SV) audio file (EN) Contact information Full Company [...]
Q3 2025 Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
Glioblastoma (GBM) remains the most aggressive and treatment-resistant primary brain tumor, with median overall survival rarely exceeding 15–20 months despite advances in surgery, imaging, and systemic therapy. The key barriers are persistent: incomplete resection, limited drug penetration across the blood–brain barrier (BBB), and a microenvironment that suppresses immune activity while promoting recurrence. In [...]
Protokoll Contact information Full Company Name: Double Bond Pharmaceutical International AB (publ) Corporate identity: 556991-6082 Stock short name: DBP B Share ISIN code: SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com/en/ Follow us on: LinkedIn, Facebook and Twitter [...]
